KIT and gastrointestinal stromal tumor: However, in advanced GIST patients with secondary mutations in KIT, the spatial variations in the catalytic centre caused by secondary mutations present steric hindrance to tyrosine kinase inhibitors (TKIs) or enhance binding affinity to ATP.10, 11, 12